Specialist practices run 8 to 14 percent no-show rates, well under the 19 percent primary care median. But each missed slot is worth $280 to $900, and the downstream procedure cascade often dwarfs the consult fee. Absolute dollar loss frequently matches or exceeds primary care.
Sources: MGMA 2024 DataDive, Medscape 2024 Compensation, CMS Physician Fee Schedule 2026.
Specialist no-show rates are not uniform. Surgical specialties run lowest (high patient stakes, short booking horizon, often pre-op work already invested). Medical specialties with chronic patient panels (cardiology, endocrinology, rheumatology) run middle. Ortho and pain run highest among non-behavioral specialties, partly because of repeat visit cadence and partly because of payer mix. The ladder below uses MGMA 2024 DataDive medians, with revenue per visit blended across commercial and Medicare from Medscape 2024 Compensation and CMS Physician Fee Schedule 2026.
| Specialty | No-show rate | Top quartile | Revenue / slot | Loss per missed slot |
|---|---|---|---|---|
| Cardiology | 11% | 7% | $280 to $350 | $315 |
| Dermatology | 12% | 8% | $250 to $320 | $285 |
| Endocrinology | 12% | 8% | $220 to $280 | $250 |
| Gastroenterology | 10% | 6% | $280 to $360 | $320 |
| Neurology | 11% | 7% | $240 to $310 | $275 |
| Orthopedics | 10% | 6% | $300 to $420 | $360 |
| Pain Management | 14% | 9% | $200 to $280 | $240 |
| Rheumatology | 12% | 8% | $240 to $310 | $275 |
| Surgery (general) | 8% | 5% | $500 to $900 | $700 |
| Urology | 9% | 6% | $260 to $340 | $300 |
Methodology: rates from MGMA 2024 DataDive Cost and Revenue Survey. Revenue per slot blended (60 percent commercial, 40 percent Medicare) using CMS Physician Fee Schedule 2026 and Medscape 2024 Compensation report averages. Loss per missed slot is the midpoint of the revenue range.
The structural reasons sit at three levels. Patient stakes are higher: a missed cardiology visit after a chest-pain ED follow-up carries direct perceived risk. Referral selection: the patient was sent by their PCP, so they cleared one motivation gate already and the appointment carries social-accountability weight. And booking horizon is shorter: most specialty visits land within 2 to 3 weeks of booking, which is the optimal forgetting-risk window per JGIM 2016 (forgetting probability rises steeply past 4 weeks).
The exception is pain management, which sits closer to primary care (14 percent) because of repeat-visit cadence, mixed payer (heavy workers' comp + Medicaid), and patient panel demographics. Pain management practices benefit disproportionately from cancellation waitlists because their referral-saturation makes filling cancelled slots same-day routine.
A primary care no-show costs roughly the consult fee plus fixed-cost-per-slot plus a modest downstream care impact. A specialist no-show is different. The consult is the gateway to a procedure pipeline. Miss the consult and you do not just lose the $300 consult: you lose the conditional probability of the $4,000 stress test, the $8,000 ablation, the $30,000 ortho surgery, the $12,000 colonoscopy.
Take cardiology. A new patient consult is $315. About 35 percent of new consults lead to an echo ($350 to $500), about 20 percent to a stress test ($1,200 to $1,800), and roughly 5 percent to a downstream cath or ablation ($8,000 to $30,000). Expected procedure-pipeline value per consult is approximately $1,800 to $2,500 when probability-weighted. A no-show consult forfeits not only the $315 but the expected $1,800 to $2,500 in downstream procedure revenue. Some patients reschedule and the cascade resumes. Many do not, and they re-enter the system through an ED visit weeks or months later, often through a different practice.
Take orthopedics with an attached ASC. A new patient ortho consult is $360. About 30 percent of new consults convert to a surgical referral within 6 months. ASC surgical revenue per case ranges $4,000 to $40,000 depending on procedure. Probability-weighted expected ASC pipeline value per ortho consult is approximately $1,800 to $3,600. A no-show consult on a Friday afternoon can cascade into an empty OR slot 4 weeks out, where each OR hour is worth $2,500 to $6,000. For a 4-surgeon ortho group, the downstream cascade of no-shows materially exceeds the consult-level cost.
The MGMA top quartile sits at 5 to 9 percent depending on specialty. Practices that get there share four operational habits that diverge in emphasis from the primary care playbook.
Most of these are vendor-agnostic. The patient engagement platforms (Weave, SolutionReach, NexHealth) all support pre-visit packets and cancellation waitlists. The referral-loop closure depends on PMS plus a habit. The card-on-file depends on payment-tokenization in your PMS.
A 4-surgeon orthopedic group running 80 clinic slots a day at $360 average revenue, 220 days a year, at a 12 percent no-show rate: 17,600 scheduled appointments, 2,112 missed, $760,320 direct revenue loss. Add unrecovered fixed cost (estimated $95,000 at the $45 per-slot rule of thumb) and the downstream surgical cascade (probability-weighted $1,800 per consult, applied to roughly half of no-showed new-patient consults that do not reschedule cleanly: about $1.1M expected pipeline loss). Total annual exposure: roughly $1.95M.
Moving from 12 percent to the top-quartile 7 percent over 6 months drops missed appointments to 1,232. Direct revenue loss falls to $443,520. Fixed cost loss falls to about $55,000. Downstream cascade roughly halves to $640K. New total exposure: about $1.14M. Annual recovery: about $810K.
Intervention cost: about $2,800 a month vendor fees for a specialty-grade engagement platform sized for 4 providers, $500 a month SMS volume, $1,200 a month for pre-visit packet automation. Annual cost roughly $54,000. Net first-year return roughly $755K. ROI: 14x in year one. The downstream surgical recovery dominates the math, which is why specialty practices that adopt the top-quartile playbook typically pay it back within month one.
Calculation is a deterministic build-up using MGMA 2024 medians and probability-weighted procedure pipeline modelling. Not a single-practice case study.
Register entries verified 2026-04-28